Stifel Reiterates Buy Rating on Boston Scientific Corporation (BSX)

Market Context

Boston Scientific Corporation operates in the Healthcare sector. The stock currently trades at $44.20 with a market capitalization of $136.0B. The stock has declined 56.1% over the past 52 weeks.

Analyst coverage from Stifel provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Boston Scientific Corporation.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Boston Scientific Corporation

Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jun 25, 2026	Stifel	Buy	N/A
Jun 24, 2026	Jefferies	Buy	N/A
Jun 16, 2026	BTIG	Buy	N/A
Jun 04, 2026	Truist Securities	Buy	N/A
Jun 03, 2026	BTIG	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View BSX Stock Page